This Trial is Conducted in Asia. The Aim of This Trial is to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs.

Trial Profile

This Trial is Conducted in Asia. The Aim of This Trial is to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL™ II Japan
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 22 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2017 Planned primary completion date changed from 3 Oct 2017 to 15 Nov 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top